Letters
Transparency of funding of patient groups
Transparency of funding of patient groups is mandatory but is not enough
BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g6301 (Published 21 October 2014) Cite this as: BMJ 2014;349:g6301
- Cinzia Colombo, researcher1,
- Paola Mosconi, head1
- 1Laboratory for Medical Research and Consumer Involvement, Department of Public Health, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy
- Cinzia.colombo{at}marionegri.it
As Arie and Mahony discuss,1 transparency is needed about the relationships between patient groups and drug companies. Our study on the websites of Italian patient groups sponsored by drug companies found that disclosure of sponsorship is scant and poorly accessible, few patient groups quantify the funding received, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.